Proteomics International has expanded IP protection for its innovative PromarkerEso blood test - a simple, non-invasive early diagnostic technology that could save countless lives. Proteomics International (ASX: PIQ) has just scored another key patent win as it ramps up efforts to detect the early signs of esophageal adenocarcinoma (EAC), an aggressive form of throat cancer that’s often linked to chronic acid reflux. The company announced the Canadian Patent Office has grante

Proteomics International has appointed healthcare and medical technology expert David Morris as the company’s new CEO and managing director. Proteomics International Laboratories (ASX: PIQ) has appointed seasoned healthcare and medtech executive David Morris as CEO and managing director to spearhead the commercial rollout of its Promarker diagnostics suite. Morris steps into the role with a strong track record in the industry, including executive leadership at Cochlear, Nanos

Proteomics International, a precision diagnostics pioneer, has achieved a key milestone in the US, with the accreditation of its Californian reference laboratory by the College of American Pathologists.

Proteomics International, an Australian pioneer in predictive medical diagnostics, has secured a US patent for its PromarkerEso, a breakthrough blood test enabling early detection of esophageal cancer.

Proteomics International says a peer-reviewed study shows its PromarkerD diabetes test reshapes medical decision-making, with high scores prompting an increase in kidney-protecting therapies.

PromarkerD is a validated blood test that can predict DKD up to four years before clinical symptoms appear, helping doctors make earlier, informed treatment decisions to improve outcomes for patients with type 2 diabetes. Perth-based Proteomics International Laboratories (ASX: PIQ) has revealed promising new clinical results demonstrating that its PromarkerD blood test effectively predicts diabetic kidney disease (DKD) risk in indigenous Australians with type 2 diabetes. A p

The Centers for Medicare & Medicaid Services, otherwise known as Medicare, which is headquartered in Baltimore in the United States. Proteomics International (ASX: PIQ) has notched up a major win in the US, with the nation’s powerful Medicare system setting a reimbursement price of US$390.75 (A$604) for the company’s groundbreaking PromarkerD predictive kidney disease blood test. The Centers for Medicare & Medicaid Services (CMS) ruling effectively hands the medical technolo

The results of Proteomics OxiDx blood testing trials are being presented today in Sydney at the Australian Physiological Society (AuPS) Annual Scientific Meeting. Proteomics International (ASX: PIQ) has delivered another strong data set from its precision diagnostics pipeline. The company has revealed that its unique, majority-owned “OxiDx” blood test for Thoroughbred racehorses shows a strong correlation between horses racing with low levels of oxidative stress and those th

Proteomics International Laboratories has received a $2.16m R&D rebate for costs incurred in the previous financial year on the research of proteins as a marker for diagnostic tests. Medical diagnostics pioneer Proteomics International Laboratories (ASX: PIQ) has filled its pockets with a further $2.2 million in cash through Australia’s research and development (R&D) rebate scheme. The company’s technology sits at the forefront of proteomics - protein-based precision medicin

Proteomics International is a medical technology company at the forefront of precision diagnostics and bio-analytical services that is making giant strides in early detection of serious diseases. After going commercial in August and September with two medical diagnostic products, Proteomics International (ASX: PIQ) is now set to see a growing pipeline of revenues. The September 2025 quarter saw the company make significant progress in commercialisation, clinical certificatio

Proteomics International Laboratories has inked an expanded research deal with the University of Melbourne and Royal Women’s Hospital to pinpoint its attack on early endometriosis identification.

Proteomics International Laboratories has achieved certification for its Perth lab, which will provide world-class test results for...

Trials of Proteomics International’s PromarkerEso blood test have delivered a near-perfect score for the detection of throat cancer...

Proteomics International Laboratories’ innovative OxiDx muscle stress test could soon be used to monitor muscle damage in thoroughbred...

Proteomics International’s PromarkerD diabetes-related blood test has just been assigned an American Medical Association billing code,...

Proteomics research scientist Martin Mead adjusts a mass spectrometer column used for its proteomics diagnostics research in the...

Proteomics International has patented PromarkerEndo, its breakthrough early diagnostic test for endometriosis, in Japan. In a milestone...

Proteomics International Laboratories has officially launched the US rollout of its PromarkerD kidney diagnostic test at a conference in...

Newly published results from Proteomics International have revealed its PromarkerEso blood test can detect early oesophageal cancer with...

Proteomics International groundbreaking, simple endometriosis blood test could revolutionise healthcare for the disease. ASX-listed...